Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2022

View Archived Issues

CRV-431 is a possible treatment approach for ALD

Thrombospondin-1 found to be involved in pathogenesis of acute-on-chronic liver failure

Albireo patents SLC10A1 and/or SLC10A2 inhibitors

Qurient Therapeutics discloses new CDK7 inhibitors

Tuojie Biotech identifies new P2X3 antagonists

Stingray Therapeutics synthesizes ENPP1 inhibitors

Roche discovers new EGFR mutant inhibitors for NSCLC

KLB as a novel druggable target for the prevention of NAFLD

CSF1R inhibition could delay muscular dystrophy progression

Extended funding supports Errium's development of therapeutics for chronic autoimmune diseases

Ildong licenses Twist VHH antibody libraries for antibody discovery in immuno-oncology

China NMPA approves IND for Henlius' anti-TIGIT Fc fusion protein HLX-53

Anti-alpha-1-antitrypsin BMN-349 reverses liver disease in a preclinical model

Sutro Biopharma generates hemiasterlin/TLR agonist dual-conjugate anti-FolR-alpha ADCs

ENT1 inhibitor reverses sporadic Alzheimer's disease in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026